Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus

Human Pathology

Volumn 31, Issue 4, 2000, Pages 434-438

  Younes, Mamoun ^a,b,c   Lechago, Juan ^a,b,c   Ertan, Atilla ^a,b,c   Finnie, Delia ^a,b,c   Younes, Anas ^a,b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Cancer; Dysplasia; Esophagus; Immunohistochemistry

Indexed keywords

FAS LIGAND;

ARTICLE; BARRETT ESOPHAGUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 0034075810     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hp.2000.6715     Document Type: Article

References (50)

1. Yonehara S. Ishii A. Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor J Exp Med 169 1989 1747 1756
2. Oehm A. Behrmann I. Falk W. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identity with the Fas antigen J Biol Chem 267 1992 10709 10715
3. Itoh N. Yonehara S. Ishii A. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis Cell 66 1991 233 243
4. Suda T. Takahashi T. Golstein P. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
5. Bamberger A.M. Schulte H.M. Thuneke I. Expression of the apoptosis-inducing Fas ligand (Fast) in human first and third trimester placenta and choriocarcinoma cells J Clin Endocrinol Metabol 82 1997 3173 3175
6. Hunt J.S. Vassmer D. Ferguson T.A. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus J Immunol 158 1997 4122 4128
7. Runic R. Lockwood C.J. Ma Y. Expression of Fas ligand by human cytotrophoblasts: Implications in placentation and fetal survival J Clin Endocrinol Metabol 81 1996 3119 3122
8. Saas P. Walker P.R. Hahne M. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain J Clin Invest 99 1997 1173 1178
9. Korbutt G.S. Elliott J.F. Rajotte R.V. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression Diabetes 46 1997 317 322
10. Lau H.T. Yu M. Fontana A. Prevention of islet allograft rejection with engineered myoblasts expressing Fast in mice Science 273 1996 109 112
11. Saporta S. Cameron D.F. Borlongan C.V. Survival of rat and porcine Sertoli cell transplants in the rat striatum without cyclosporine-A immunosuppression Exp Neurol 146 1997 299 304
12. Gratas C. Tohma Y. Barnas C. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer Cancer Res 58 1998 2057 2062
13. Leithauser F. Dhein J. Mechtersheimer G. Constitutive and induced expression of APOA, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells Lab Invest 69 1993 415 429
14. Moller P. Korev K. Leithauser F. Expression of APO-1 (CD95), a member of the NGF/TNF receptor super family, in normal and neoplastic colon epithelium IntJ Cancer 57 1994 371 377
15. Vollmers H.P. Dammrich J. Hensel F. Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma Cancer 79 1997 433 440
16. Moller P. Walczak H. Riedl S. Paneth cells express high levels of Cd95 ligand transcripts: A unique property among gastrointestinal epithelia Am J Pathol 149 1996 9 13
17. Niehans G.A. Brunner T. Frizelle S.P. Human lung carcinomas express Fas ligand Cancer Res 57 1997 1007 1012
18. Gratas C. Tohma Y. Vanmeir E.G. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors Brain Pathol 7 1997 863 869
19. Shiraki K. Tsuji N. Shioda T. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas Proc Natl Acad Sci U S A 94 1997 6420 6425
20. Hahne M. Rimoldi D. Schroter M. Melanoma cell expression of Fas (Apo-l/CD95) ligand: Implications for tumor immune escape Science 274 1996 1363 1366
21. Ekmekcioglu S. Okcu M.F. Colome-Grimmer M.I. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10 Melanoma Res 9 1999 261 272
22. Strand S. Hofmann W.J. Hug H. Lymphocyte apoptosis induced by Cd95 (Apo-l/Fas) ligand-expressing tumor cells: A mechanism of immune evasion Nature Med 2 1996 1361 1366
23. Hughes S.J. Nambu Y. Soldes O.S. Fas/Apo-l (Cd95) is not translocated to the cell membrane in esophageal adenocarcinoma Cancer Res 57 1997 5571 5578
24. Ungefroren H. Voss M. Jansen M. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis Cancer Res 58 1998 1741 1749
25. Chouaib S. Asselinpaturel C. Mamichouaib F. The host-tumor immune conflict: From immunosuppression to resistance and destruction Immunol Today 18 1997 493 497
26. Green D.R. Ware C.F. Fas-ligand: Privilege and peril Proc Natl Acad Sci U S A 94 1997 5986 5990
27. Griffith T.S. Ferguson T.A. The role of FasL-induced apoptosis in immune privilege Immunol Today 18 1997 240 244
28. Nagata S. Fas ligand and immune evasion Nature Med 2 1996 1306 1307
29. Walker P.R. Saas P. Dietrich P.Y. Role of Fas ligand (Cd95I) in immune escape: The tumor cell strikes back—Commentary J Immunol 158 1997 4521 4524
30. Younes M. Schwartz M.R. Finnie D. Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus Hum Pathol 30 1999 1309 1313
31. Haggitt R.C. Barrett's esophagus, dysplasia, and adenocarcinoma Hum Pathol 25 1994 982 993
32. Younes M. Schwartz M.R. Ertan A. Fas ligand expression in esophageal carcinomas and their lymph node metastases Cancer 88 2000 524528
33. Houghton J.A. Harwood F.G. Gibson A.A. The Fas signaling pathway is functional in colon carcinoma cells and induces apoptosis Clin Cancer Res 3 1997 2205 2209
34. Choi C. Park J.Y. Lee J. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-alpha, or IFN-gamma J Immunol 162 1999 1889 1895
35. Ohtsuki T. Micallef M.J Kohno K. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells Anticancer Res 17 1997 3253 3258
36. Refaeli Y. Van Parijs L. London C.A. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis Immunity 8 1998 615 623
37. Akasaka Y. Ishikawa Y. Kato S. Induction of Fas-mediated apoptosis in a human renal epithelial cell line by interferon-gamma: Involvement of Fas-mediated apoptosis in acute renalrejection Mod Pathol 11 1998 1107 1114
38. Buechner S.A. Wernli M. Harr T. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-l/Fas)-CD95 ligand-induced suicide J Clin Invest 100 1997 2691 2696
39. Dai C.H. Price J.O. Brunner T. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis Blood 91 1998 1235 1242
40. Lepri E. Delfino D.V. Migliorati G. Functional expression of Fas on mouse bone marrow stromal cells: Upregulation by tumor necrosis factor-alpha and interferon-gamma Exp Hematol 26 1998 1202 1208
41. Maciejewski J. Selleri C. Anderson S. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine mediatedhematopoietic suppression in vitro Blood 85 1995 3183 3190
42. Mizuno M. Yoshida J. Tumor necrosis factor-alpha gene transfer augments anti-Fas antibody-mediated apoptosis in human glioma cells Jpn J Cancer Res 87 1996 543 547
43. Jhala N. Jhala D. Liu L. Expression of Fas antigen in gastritis Mod Pathol 12 1999 76A
44. Wong G.H. Goeddel D.V. Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways J Immunol 152 1994 1751 1755
45. Clement M.V. Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death: Similarities and distinctions J Exp Med 180 1994 557 567
46. Schulze-Osthoff K. Krammer P.H. Droge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death EMBO J 13 1994 4587 4596
47. Abreu-Martin M.T. Vidrich A. Lynch D.H. Divergent induction of apoptosis and IL-8 secretion in HT 29 cells in response to TNF-alpha and ligation of Fas antigen J Immunol 155 1995 4147 4154
48. Enari M. Hug H. Hayakawa M. Different apoptotic pathways mediated by Fas and the tumor-necrosis-factor receptor. Cytosolic phospholipase A2 is not involved in Fas-mediatedapoptosis EurJ Biochem 236 1996 533 538
49. Laouar A. Glesne D. Huberman E. Involvement of protein kinase C-beta and ceramide in tumor necrosis factor-alpha-induced but not Fas-induced apoptosis of human myeloid leukemia cells J Biol Chem 274 1999 23526 23534
50. Van Molle W. Libert C. Fiers W. Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice J Immunol 159 1997 3555 3564